Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial.

CONCLUSIONS: Although underpowered, this study demonstrates a clinically important analgesic signal. TTX may provide clinically meaningful analgesia for patients who have persistent moderate to severe cancer pain despite best analgesic care. This clinical study is registered with ClinicalTrials.gov (NCT00725114). PMID: 28555092 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/28555092?dopt=Abstract

Source: Pain Research and Management - June 1, 2017 Category: Anesthesiology Authors: Hagen NA, Cantin L, Constant J, Haller T, Blaise G, Ong-Lam M, du Souich P, Korz W, Lapointe B Tags: Pain Res Manag Source Type: research